Selank vs Semax: How the Russian Nootropic Peptides Actually Compare

same lab tradition, different targets

Selank and Semax both came out of the V.N. Orekhovich Institute of Biomedical Chemistry in Moscow during the 1990s. Both are short, modified peptides — natural sequences that have been chemically tweaked to make them more stable and longer-lasting in the body.

This is a generally underappreciated piece of the story. Most peptides in the current biohacker conversation came out of Western pharmaceutical research. Selank and Semax came out of a parallel Russian research tradition that, for various Cold War-era reasons, didn't heavily integrate with Western biomedical literature until much later. As a result, both peptides have substantial Russian-language research behind them that's only partially available in English translation. The published Western literature is real but smaller than the actual research base.

This matters when you're evaluating these molecules. A claim like Selank has decades of clinical use in Russia is true — it's based on a domestic Russian medical tradition where Selank has been used as an anxiety treatment for years. But the FDA-relevant evidence base — the kind of evidence required to register a drug in the US — is much thinner than the total research output suggests.

selank — what it actually targets

Selank (Tuftsin-Pro-Gly-Pro) is a synthetic analog of tuftsin, a naturally occurring four-amino-acid peptide produced by the spleen. Natural tuftsin is involved in immune modulation, particularly macrophage function. Selank extends and stabilizes that activity, and adds central-nervous-system effects that the original tuftsin doesn't have.

The core mechanism for Selank's anxiety effects appears to involve modulation of GABAergic signaling — the same neurotransmitter system benzodiazepines act on, but through a different mechanism. Selank also affects monoamine metabolism (serotonin and dopamine pathways) and may upregulate BDNF expression in certain brain regions.^[1]

In the published anxiety research — most of it Russian, with several English translations and reviews — Selank shows anxiolytic effects comparable in magnitude to medazepam (a benzodiazepine) without the sedation, dependence, or memory effects characteristic of benzodiazepines. That's the major appeal of the molecule clinically: anxiety relief without the cognitive cost.^[2]

There's also a smaller but consistent literature on Selank's immune-modulating effects, which trace back to its tuftsin parent. Selank appears to enhance certain macrophage and natural-killer-cell activities, with possible relevance for chronic infection or post-viral recovery contexts. This area is less developed than the anxiety story but is mechanistically grounded.

semax — different target, different profile

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic fragment of ACTH (adrenocorticotropic hormone), specifically the 4-7 region with a Pro-Gly-Pro tail to stabilize it. It does NOT have ACTH's hormonal effects — the modification specifically removes the steroid-stimulating activity while preserving and amplifying the neurotrophic and cognitive effects.

The core mechanism for Semax involves several pathways that affect cognition and neuroprotection. Semax upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — proteins that support neuron survival and synaptic plasticity. It also appears to modulate cholinergic signaling, the neurotransmitter system most directly involved in attention and memory consolidation.^[1]

In published research, Semax has been studied for cognitive enhancement in healthy subjects, neuroprotection in stroke patients (where it's actually approved as a stroke treatment in Russia), and in attention-deficit and developmental contexts. The cognitive enhancement signal in healthy users is modest but reasonably consistent — improvements in attention, working memory, and processing speed during demanding tasks. The neuroprotection signal in stroke is the strongest clinical signal, with several Russian clinical trials showing reduced neurological deficit and faster recovery when Semax is administered in the acute phase.

when each one makes sense

The shorthand that often shows up on forums is Selank for anxiety, Semax for focus, and that's a defensible first-pass mapping. The longer version:

Selank fits when: - Primary concern is anxiety, particularly the kind that interferes with cognition - Sleep is affected by anxiety (Selank doesn't sedate but reduces the underlying arousal) - Immune function is part of the picture (post-viral, chronic infection) - Existing benzodiazepine use needs to be reduced

Semax fits when: - Primary concern is cognitive performance or neurological recovery - Demanding work or study is the use case - There's a neuroprotective rationale (post-concussion, post-stroke, neurodegenerative concerns) - ADHD-spectrum attention difficulties (it's been studied here, with the strongest evidence in childhood ADHD in Russian research)

Users do sometimes use them together — Semax in the morning for cognitive support, Selank in the evening for anxiety. Whether that combination is additive, redundant, or potentially synergistic isn't well-characterized in published research. It's empirical user experience, not validated protocol.

both are intranasal

Both peptides are typically administered as intranasal spray. That's the clinical route in Russian medical practice and the one the published research uses. Intranasal delivery is particularly important for these molecules because of the brain-penetration question.

Most peptides have poor brain penetration when given orally or by injection — the blood-brain barrier is selective, and large polar molecules like peptides generally don't cross it well. Intranasal delivery partially bypasses this problem because olfactory neurons provide a more direct route from the nasal mucosa to the brain. This is why intranasal oxytocin gets used in research where the goal is brain-level effects.

For Selank and Semax specifically, intranasal is what the Russian clinical experience has used and what the published efficacy data is based on. Oral and injectable forms exist but have less research support and less clinical track record.

where the evidence base is genuinely thin

Several things are honestly less established than enthusiastic marketing suggests:

Long-term safety. The Russian clinical experience is decades long, but the published long-term safety data — the kind of multi-year follow-up studies the FDA wants — is limited. Both peptides appear clean acutely, but extended daily use over years isn't well-characterized.

Dose-response in healthy users. Most research is in clinical populations (anxiety patients for Selank, stroke patients for Semax). Dose-response in healthy users wanting cognitive enhancement or anxiety management is more empirical than research-backed. The doses used by biohackers are often extrapolated from clinical dosing.

Western validation. The bulk of the efficacy literature is Russian. Several reviews in Western journals have summarized the Russian work, but independent replication in Western clinical trials has been limited. This isn't proof the work is wrong — Russian biomedical research is real research — but it's a known gap that responsible evaluation acknowledges.

Combination effects. Using Selank and Semax together is common practice but not a researched protocol. Whether they interact, augment each other, or are simply additive isn't characterized.

regulatory status in the us

Both Selank and Semax are on the FDA's Category 2 bulk drug substances list as of 2023. That means 503A compounding pharmacies aren't currently permitted to produce them for individual patient prescriptions. Neither is FDA-approved as a finished pharmaceutical product (Semax has Russian regulatory approval for stroke, but no US approval).

In February 2026, the administration announced intent to move 14 peptides back to Category 1. Whether Selank and Semax are included in the final published list is something to watch — the formal FDA reclassification publication is the authoritative answer.

The underground research-chemical market for both peptides is large internationally, particularly in Eastern Europe. As with all underground sourcing, the contamination, mislabeling, and dosage-accuracy risks are real. The legitimate path is to wait for the regulatory situation to resolve.

where this leaves you

Selank and Semax are mechanistically interesting peptides with real but incomplete research support. The Russian clinical tradition is a valid evidence base — it's just not fully integrated with Western FDA-style evidence requirements.

Selank's anxiolytic effects appear well-characterized at the mechanism and clinical level. Semax's cognitive and neuroprotective effects have a strong stroke-recovery signal in clinical trials and a more modest healthy-user enhancement signal. Both are intranasal in the established protocols. Both are currently outside the legal US compounding system pending regulatory action.

For someone thinking about these molecules in their own context: Selank is a real anxiety tool with a different profile than benzodiazepines. Semax is a real cognitive-support and neuroprotection tool with a different profile than caffeine or modafinil. Neither replaces standard treatments for serious clinical conditions. Both are interesting adjuncts in the right context.

For more on Selank specifically in anxiety contexts, see Selank for anxiety and Selank for pre-performance anxiety. For the broader regulatory framework, see are peptides legal in 2026.